CR9956A - Metodos y composiciones para modular la hemostasia - Google Patents

Metodos y composiciones para modular la hemostasia

Info

Publication number
CR9956A
CR9956A CR9956A CR9956A CR9956A CR 9956 A CR9956 A CR 9956A CR 9956 A CR9956 A CR 9956A CR 9956 A CR9956 A CR 9956A CR 9956 A CR9956 A CR 9956A
Authority
CR
Costa Rica
Prior art keywords
methods
hemostasy
modulate
compositions
variants
Prior art date
Application number
CR9956A
Other languages
English (en)
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of CR9956A publication Critical patent/CR9956A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se presentan variantes del factor Xa y metodos para su uso.
CR9956A 2005-11-15 2008-05-07 Metodos y composiciones para modular la hemostasia CR9956A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15

Publications (1)

Publication Number Publication Date
CR9956A true CR9956A (es) 2008-08-21

Family

ID=38049397

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9956A CR9956A (es) 2005-11-15 2008-05-07 Metodos y composiciones para modular la hemostasia

Country Status (25)

Country Link
US (4) US8383386B2 (es)
EP (4) EP1948690B1 (es)
JP (4) JP5823088B2 (es)
KR (4) KR20160029135A (es)
CN (1) CN101356192B (es)
AU (1) AU2006315175B2 (es)
BR (1) BRPI0618654B1 (es)
CA (2) CA2629491C (es)
CR (1) CR9956A (es)
DK (1) DK1948690T3 (es)
EC (1) ECSP088452A (es)
ES (2) ES2496567T3 (es)
GT (1) GT200800065A (es)
IL (1) IL191310A (es)
MX (3) MX336958B (es)
MY (1) MY162181A (es)
NO (3) NO345177B1 (es)
NZ (1) NZ568108A (es)
PL (1) PL1948690T3 (es)
PT (1) PT1948690E (es)
RU (2) RU2008123398A (es)
SI (1) SI1948690T1 (es)
SV (1) SV2008002906A (es)
WO (1) WO2007059513A2 (es)
ZA (1) ZA200804026B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
JP6514893B2 (ja) 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
KR102049900B1 (ko) 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
CN112195169A (zh) * 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
US20160235824A1 (en) * 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
CN105934250A (zh) 2014-01-24 2016-09-07 辉瑞公司 治疗脑内出血的组合物和方法
NZ727444A (en) * 2014-05-26 2021-12-24 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
WO2016028872A2 (en) 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
WO2018022844A2 (en) 2016-07-27 2018-02-01 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
EP4453012A1 (en) 2021-12-22 2024-10-30 Royal College of Surgeons in Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
JP5833448B2 (ja) * 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用

Also Published As

Publication number Publication date
US8383386B2 (en) 2013-02-26
EP1948690A2 (en) 2008-07-30
US20180251745A1 (en) 2018-09-06
KR101574042B1 (ko) 2015-12-03
HK1128699A1 (en) 2009-11-06
IL191310A (en) 2015-06-30
JP5957167B2 (ja) 2016-07-27
CN101356192B (zh) 2013-09-11
MY162181A (en) 2017-05-31
RU2570547C2 (ru) 2015-12-10
RU2011130932A (ru) 2013-01-27
EP2431390B1 (en) 2015-08-12
NO20200670A1 (no) 2008-07-30
MX336958B (es) 2016-02-05
KR101600158B1 (ko) 2016-03-08
GT200800065A (es) 2008-11-03
JP2009515559A (ja) 2009-04-16
NO345177B1 (no) 2020-10-26
CA2971971A1 (en) 2007-05-24
DK1948690T3 (da) 2014-09-01
JP6571735B2 (ja) 2019-09-04
HK1165444A1 (en) 2012-10-05
MX2008006313A (es) 2008-11-06
US20160362673A1 (en) 2016-12-15
BRPI0618654B1 (pt) 2021-10-19
WO2007059513A3 (en) 2007-11-29
US9896676B2 (en) 2018-02-20
NZ568108A (en) 2011-09-30
JP2014073127A (ja) 2014-04-24
KR20140115374A (ko) 2014-09-30
US20090175931A1 (en) 2009-07-09
ES2496567T3 (es) 2014-09-19
ES2549929T3 (es) 2015-11-03
BRPI0618654A8 (pt) 2019-01-15
PT1948690E (pt) 2014-09-08
EP1948690B1 (en) 2014-06-11
SI1948690T1 (sl) 2014-09-30
ECSP088452A (es) 2008-07-30
JP2018033459A (ja) 2018-03-08
KR20160029135A (ko) 2016-03-14
AU2006315175A1 (en) 2007-05-24
KR20140005383A (ko) 2014-01-14
EP2431390A1 (en) 2012-03-21
US9410137B2 (en) 2016-08-09
AU2006315175B2 (en) 2013-02-07
ZA200804026B (en) 2009-10-28
CA2629491A1 (en) 2007-05-24
KR101827569B1 (ko) 2018-02-09
BRPI0618654A2 (pt) 2011-09-06
JP5823088B2 (ja) 2015-11-25
CN101356192A (zh) 2009-01-28
RU2008123398A (ru) 2009-12-27
KR20080078664A (ko) 2008-08-27
SV2008002906A (es) 2008-10-22
NO20082182L (no) 2008-07-30
EP2423224A1 (en) 2012-02-29
EP1948690A4 (en) 2009-06-17
MX337059B (es) 2016-02-09
EP2423224B1 (en) 2015-08-12
NO20200671A1 (no) 2008-07-30
EP2431389A1 (en) 2012-03-21
JP2016005464A (ja) 2016-01-14
WO2007059513A2 (en) 2007-05-24
CA2629491C (en) 2019-05-07
JP6236194B2 (ja) 2017-11-22
US20140120155A1 (en) 2014-05-01
PL1948690T3 (pl) 2014-11-28

Similar Documents

Publication Publication Date Title
GT200800065A (es) Métodos y composiciones para modular la hemostasia
CR11373A (es) COMPUESTOS DE TIENOPIRIMIDINA Y PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE mTOR CINASA Y PI3 CINASA
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CR10213A (es) Moduladores de la proteína quinasa aurora
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP088558A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
UY30748A1 (es) Compuesto0s novedosos
NO20092637L (no) Fremgangsmater for behandling
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
NO20084334L (no) Farmasoytiske sammensetninger
ATE502921T1 (de) Substituierte indole
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
UY32918A (es) Nuevos compuestos de 2-piridona
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CL2008003265A1 (es) Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores.
ATE544759T1 (de) 5-pyridinon-substituierte indazole und pharmazeutische zusammensetzungen davon
UY30610A1 (es) Moduladores de mglur5
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
EA200870515A1 (ru) Моноциклические гетероарильные соединения
CL2009001804A1 (es) Uso de un copolimero de vinilamina-vinilformamida y un portador para preparar una composicion destinada a fortalecer las fibras queratinosas.
BRPI0514586A (pt) triazolftalazinas
UY29872A1 (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas